Pregabalin Capsule
Product Images NDC 50090-6503

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-6503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906503)

Pregabalin 100 mg capsules label from A-S Medication Solutions. The label indicates each capsule contains 100 mg of pregabalin. The package includes 60 capsules for oral use. Storage instructions specify keeping the product at 77 degrees Fahrenheit. The label also shows an NDC code 50090-6503-0 and packaging details, including the location of the labeler in Libertyville, IL.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical formula displaying the calculation for creatinine clearance (CLCr). It includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 specifically for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line chart depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses and placebo. The chart compares Pregabalin 200 mg, 100 mg, and 25 mg three times a day with placebo, showing higher patient improvement percentages at increased Pregabalin doses.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day (dashed line) with placebo (dotted line). The graph shows the trend of patient improvement across increasing levels of pain reduction.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This chart depicts the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared with a placebo. Multiple descending curves illustrate varying patient response rates by dose level.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A curve graph depicting percent improvement in pain from baseline versus percent of patients improved. The graph compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). Percent patient improvement decreases as pain improvement percentage increases along the x-axis.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line), showing patient response across pain improvement percentages.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart showing responder rates (%) from two studies, E1 and E3. Study E1 compares placebo to pregabalin doses of 50 mg, 150 mg, 300 mg, and 600 mg per day (BID dosing), with responder rates increasing from 14% for placebo up to 51% for 600 mg. Study E3 compares placebo and pregabalin 600 mg per day dosed BID and TID, with responder rates of 9% (placebo), 43% (BID), and 49% (TID). Sample sizes are indicated below each bar.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction (median percentage change from baseline) plotted against pregabalin dose (mg/day). Four dosing regimens labeled as Stukly E1BID, E2BID, E3BID, and E3TID are represented by different symbols. The graph illustrates increasing seizure reduction with higher doses, with p-values indicating statistical significance next to data points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A cumulative distribution plot showing percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo. The y-axis represents percent of patients improved, and the x-axis represents percent improvement in pain. Lines differentiate the responses for each dose and placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR over a 180-day period. The graph compares two groups: Pregabalin and Placebo, with the Pregabalin group maintaining a higher percentage of subjects without LTR throughout the study duration. The x-axis represents days, and the y-axis represents the estimated percentage without LTR (0% to 100%).*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved versus the percent improvement from baseline to week 12 with two treatment groups labeled Pregabalin (solid line) and Placebo (dotted line). The y-axis represents the percent of subjects improved from 0 to 100, and the x-axis represents percent improvement from baseline to week 12 BOCF (Baseline Observation Carried Forward).*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups over percent improvement from baseline to Week 16 using BOCF. The vertical axis represents the percent of subjects improved (0 to 100%), and the horizontal axis shows percent improvement from 0 to ≥100. Pregabalin consistently shows a higher percentage of subjects improved compared to placebo across the range.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin, showing its molecular arrangement with carbon, hydrogen, nitrogen, and oxygen atoms represented.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.